Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Paul Paik, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Miami Cancer Institute Baptist Health South Florida
Miami, Florida, United States
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Commack
Commack, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan Kettering Rockville Centre
Rockville Centre, New York, United States
- Memorial Sloan Kettering Westchester
Sleepy Hollow, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2015
- Primary completion
- 31 May 2019
- Completion
- 31 May 2019
- Last update posted
- 12 Jan 2021
- Registered enrollment
- 40
- Registry id
- NCT02525653
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.